Innovation is the best medicine Built on a foundation of deep research, RTW invests with innovative companies looking to bring important new products to patients. OUR FOCUS ON INNOVATIVE MEDICINE We have developed expertise through our comprehensive study of industry and academic efforts in targeted areas of significant innovation. By focusing our energies, we believe … Home Page Read More »
Investment Type: Venture Capital
Mentions in press and media 21
| Date | Title | Description |
| 20.01.2025 | Umoja Biopharma's $100 Million Leap: A New Era for In Vivo CAR T Cell Therapies | Umoja Biopharma is on the rise. The Seattle-based company has just secured $100 million in Series C financing. This is not just a number; it’s a statement. It signals a bold step forward in the world of biotechnology. The funding round was ... |
| 20.01.2025 | Umoja Biopharma Raises $100M in Series C Financing | Umoja Biopharma, a Seattle, WA-based clinical-stage company which specializes in vivo cell therapies, raised $100M Series C financing. The round was led by Double Point Ventures and DCVC Bio, with participation from new and existing investo... |
| 14.01.2025 | Windward Bio: Charting New Waters in Immunology with $200 Million Series A Financing | In the vast ocean of biopharmaceutical innovation, Windward Bio has set sail with a robust $200 million Series A financing. This private, clinical-stage company aims to navigate the turbulent waters of immunological diseases, focusing on se... |
| 13.01.2025 | Windward Bio launches with $200 million Series A financing round | Windward Bio’s lead candidate, WIN378, which has been in-licensed from Kelun-Biotech and Harbour BioMed, is a potential best-in-class, long-acting monoclonal antibody targeting the ligand of thymic stromal lymphopoietin (TSLP) that has the... |
| 10.01.2025 | Numab Therapeutics: A Financial Surge in the Fight Against Cancer | In the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c... |
| 09.01.2025 | Numab raises additional CHF50 million | In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo... |
| 20.12.2024 | Ottimo Pharma: A New Dawn in Cancer Treatment with $140 Million Boost | In the world of biotechnology, every dollar counts. Ottimo Pharma, a New York City-based biotech firm, has just raised over $140 million in a Series A funding round. This infusion of capital is not just a financial milestone; it’s a beacon ... |
| 20.12.2024 | Ottimo Pharma: Over $140 Million (Series A) Raised To Advance Bifunctional Medicines | Ottimo Pharma – a private biotech company pioneering bifunctional medicines to extend the lives of people with cancer – announced the completion of a Series A financing round of over $140 million. The funding round was led by OrbiMed, Avoro... |
| 15.11.2024 | The Surge of Innovation: Beta Bionics and PMWeb Secure Major Investments | In the fast-paced world of technology and healthcare, two companies have recently made headlines by securing significant funding. Beta Bionics and PMWeb are not just raising capital; they are paving the way for transformative solutions in d... |
| 15.11.2024 | Beta Bionics Closes $60M Series E Financing | Beta Bionics, an Irvine, CA-based company which specializes in the development of advanced diabetes management solutions, raised $60M in Series E funding. The round was led by Wellington Management. Previous investors Eventide Asset Managem... |
Show more